Erelzi (etanercept biosimilar) is available in Canada for the treatment of multiple inflammatory diseases

August 21, 2017 2:21 PM

erelzi-sandoz-biosimilarnews-logo

Sandoz, a Novartis division, announced today that Erelzi (etanercept) is now available in Canada.

In April 2017, Health Canada granted Erelzi a Notice of Compliance for treatment of moderately to severely active rheumatoid arthritis (RA) in adults with or without methotrexate and for reducing signs and symptoms of active ankylosing spondylitis (AS). Moreover, Erelzi is the only biosimilar approved for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA)  in patients aged 4 to 17 years who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs), a condition that affects about one in 1,000 children in Canada.

“The EGALITY study has shown that Erelzi is safe and effective, and switching patients from Enbrel to Erelzi can be performed safely without any loss of efficacy,” said Dr. Janet Pope, Professor of Medicine in the Division of Rheumatology, Epidemiology, and Biostatistics at the University of Western Ontario, Schulich School of Medicine, London. “For patients living with debilitating inflammatory arthritis diseases, this is an appropriate time to discuss new treatment and care options.”

Erelzi is available in a pre-filled syringe (PFS) and a pre-filled pen (PFP), SensoReady®, which has an ergonomic device for patients with limited dexterity. SensoReady is available in 25 mg and 50 mg PFS, and is the only etanercept available in a 25 mg PFS.

“Biologics have revolutionized the treatment and prevention of many disabling and life-threatening diseases. However, they are contributing to the rising costs of healthcare, and this may restrict access to these important medicines,” said Michel Robidoux, President and General Manager of Sandoz Canada.  “Unfortunately, as it stands today, not all Canadians living with debilitating disease have the same access to biologics. There is a growing population that has a relatively high prevalence of immunological diseases, such as rheumatoid arthritis. Launching Erelzi is another concrete example of how Sandoz is making access happen by offering high-quality medicines at a more affordable price, which will deliver important savings to healthcare system.”

Source: Sandoz press release

 

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!